Chimeric Therapeutics Ltd Ends June Quarter Healthy With $ 22.4 Million As It Grows CLTX CAR T
The funds will support the company's efforts to advance the development of CLTX CAR T and initiate the development of a cell therapy pipeline.
() ended the June quarter in a healthy financial position with $ 22.4 million in cash and…